Jane Antony

Employment

• Stanford University Postdoctoral Research Fellow
  2017 - Present
• Imperial College London Research Associate
  2016 - 2017

Education

• Imperial College London Ph.D
  2012 - 2016
• National University of Singapore B.Eng
  2008 - 2012

Projects & Funding

Projects & funding information is unavailable.

Publications (8)

• LMO2 is critical for early metastatic events in breast cancer
  2021 DOI: 10.1101/2021.05.26.443198
  +Save
• Inactivating mutations and X-ray crystal structure of the tumor suppressor OPCML reveal cancer-associated functions
  Nature Communications 2019 DOI: 10.1038/s41467-019-10966-8
  +Save
• Epithelial-to-mesenchymal transition: lessons from development, insights into cancer and the potential of EMT-subtype based therapeutic intervention
  Physical Biology 2019 DOI: 10.1088/1478-3975/ab157a
  +Save
• Usp16 modulates Wnt signaling in primary tissues through Cdkn2a regulation
  Scientific Reports 2018 DOI: 10.1038/s41598-018-34562-w
  +Save
• The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer
  EMBO reports 2018 DOI: 10.15252/embr.201745670
  +Save
• AXL-driven EMT state as a targetable conduit in cancer
  Cancer Research 2017 DOI: 10.1158/0008-5472.CAN-17-0392
  +Save
• The tumor-suppressor protein OPCML potentiates anti–EGFR- and anti–HER2-targeted therapy in HER2-positive ovarian and breast cancer
  Molecular Cancer Therapeutics 2017 DOI: 10.1158/1535-7163.MCT-17-0081
  +Save
• The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer
  Science Signaling 2016 DOI: 10.1126/scisignal.aaf8175
  +Save